One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2021-146079
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 1 |
Affiliation: Mayo Clinic, Duke Medical Center, Northwestern University, The University of Texas MD Anderson Cancer Center, University of Nebraska Medical Center, City of Hope, MEI Pharma (United States), Medical College of Wisconsin, Dana-Farber Cancer Institute, City Of Hope National Medical Center, New York UniversityA Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
